Sophon's pathology model reads tumor biology from standard biopsy slides
Sophon CEO Thomas Ebrahimi argues that mapping each tumor's biology from existing pathology slides can deliver useful cancer care sooner than AI-designed drugs, though clinical validation remains pending.